Limits...
(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients.

Kurihara H, Hamada A, Yoshida M, Shimma S, Hashimoto J, Yonemori K, Tani H, Miyakita Y, Kanayama Y, Wada Y, Kodaira M, Yunokawa M, Yamamoto H, Shimizu C, Takahashi K, Watanabe Y, Fujiwara Y, Tamura K - EJNMMI Res (2015)

Bottom Line: The HER2 specificity of (64)Cu-DOTA-trastuzumab was demonstrated in one patient by autoradiography, immunohistochemistry, and LC-MS/MS.Cu-DOTA-trastuzumab PET could be a potential noninvasive procedure for serial identification of metastatic brain lesions in patients with HER2-positive breast cancer.UMIN000004170.

View Article: PubMed Central - PubMed

Affiliation: Department of Diagnostic Radiology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan.

ABSTRACT

Background: The purpose of this study was to determine whether brain metastases from HER2-positive breast cancer could be detected noninvasively using positron emission tomography (PET) with (64)Cu-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-trastuzumab.

Methods: PET was performed on five patients with brain metastases from HER2-positive breast cancer, at 24 or 48 h after the injection of approximately 130 MBq of the probe (64)Cu-DOTA-trastuzumab. Radioactivity in metastatic brain tumors was evaluated based on PET images in five patients. Autoradiography, immunohistochemistry (IHC), and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis were performed in one surgical case to confirm HER2 specificity of (64)Cu-DOTA-trastuzumab.

Results: Metastatic brain lesions could be visualized by (64)Cu-DOTA-trastuzumab PET in all of five cases, which might indicated that trastuzumab passes through the blood-brain barrier (BBB). The HER2 specificity of (64)Cu-DOTA-trastuzumab was demonstrated in one patient by autoradiography, immunohistochemistry, and LC-MS/MS.

Conclusions: Cu-DOTA-trastuzumab PET could be a potential noninvasive procedure for serial identification of metastatic brain lesions in patients with HER2-positive breast cancer.

Trial registration: UMIN000004170.

No MeSH data available.


Related in: MedlinePlus

Histological distributions of64Cu-radioactivity and HER2-positive tumor cells. Left column: HE staining; middle column: IHC; right column: autoradiography. Loupe images (upper panels) show identical distribution of radioactivity and location of HER2-positive tumor cells for HE stain, IHC, and autoradiography samples. Magnified images (lower panels, ×200) confirmed the radioactivity and HER2-positive status of tumor cells.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4385241&req=5

Fig3: Histological distributions of64Cu-radioactivity and HER2-positive tumor cells. Left column: HE staining; middle column: IHC; right column: autoradiography. Loupe images (upper panels) show identical distribution of radioactivity and location of HER2-positive tumor cells for HE stain, IHC, and autoradiography samples. Magnified images (lower panels, ×200) confirmed the radioactivity and HER2-positive status of tumor cells.

Mentions: In patient no. 5, a metastatic brain tumor of 2.8 × 3.1 cm was visualized by 64Cu-DOTA-trastuzumab PET imaging at 24 h after injection (Figure 2). PET imaging was not performed at 48 h after injection in this case because of the scheduled surgical operation. An autoradiogram of the frozen section prepared from the removed brain tumor specimen revealed high accumulation in the area where HER2-positive cells were seen by IHC (Figure 3), confirming the HER2 specificity of 64Cu-DOTA-trastuzumab PET imaging in a human subject.Figure 3


(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients.

Kurihara H, Hamada A, Yoshida M, Shimma S, Hashimoto J, Yonemori K, Tani H, Miyakita Y, Kanayama Y, Wada Y, Kodaira M, Yunokawa M, Yamamoto H, Shimizu C, Takahashi K, Watanabe Y, Fujiwara Y, Tamura K - EJNMMI Res (2015)

Histological distributions of64Cu-radioactivity and HER2-positive tumor cells. Left column: HE staining; middle column: IHC; right column: autoradiography. Loupe images (upper panels) show identical distribution of radioactivity and location of HER2-positive tumor cells for HE stain, IHC, and autoradiography samples. Magnified images (lower panels, ×200) confirmed the radioactivity and HER2-positive status of tumor cells.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4385241&req=5

Fig3: Histological distributions of64Cu-radioactivity and HER2-positive tumor cells. Left column: HE staining; middle column: IHC; right column: autoradiography. Loupe images (upper panels) show identical distribution of radioactivity and location of HER2-positive tumor cells for HE stain, IHC, and autoradiography samples. Magnified images (lower panels, ×200) confirmed the radioactivity and HER2-positive status of tumor cells.
Mentions: In patient no. 5, a metastatic brain tumor of 2.8 × 3.1 cm was visualized by 64Cu-DOTA-trastuzumab PET imaging at 24 h after injection (Figure 2). PET imaging was not performed at 48 h after injection in this case because of the scheduled surgical operation. An autoradiogram of the frozen section prepared from the removed brain tumor specimen revealed high accumulation in the area where HER2-positive cells were seen by IHC (Figure 3), confirming the HER2 specificity of 64Cu-DOTA-trastuzumab PET imaging in a human subject.Figure 3

Bottom Line: The HER2 specificity of (64)Cu-DOTA-trastuzumab was demonstrated in one patient by autoradiography, immunohistochemistry, and LC-MS/MS.Cu-DOTA-trastuzumab PET could be a potential noninvasive procedure for serial identification of metastatic brain lesions in patients with HER2-positive breast cancer.UMIN000004170.

View Article: PubMed Central - PubMed

Affiliation: Department of Diagnostic Radiology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan.

ABSTRACT

Background: The purpose of this study was to determine whether brain metastases from HER2-positive breast cancer could be detected noninvasively using positron emission tomography (PET) with (64)Cu-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-trastuzumab.

Methods: PET was performed on five patients with brain metastases from HER2-positive breast cancer, at 24 or 48 h after the injection of approximately 130 MBq of the probe (64)Cu-DOTA-trastuzumab. Radioactivity in metastatic brain tumors was evaluated based on PET images in five patients. Autoradiography, immunohistochemistry (IHC), and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis were performed in one surgical case to confirm HER2 specificity of (64)Cu-DOTA-trastuzumab.

Results: Metastatic brain lesions could be visualized by (64)Cu-DOTA-trastuzumab PET in all of five cases, which might indicated that trastuzumab passes through the blood-brain barrier (BBB). The HER2 specificity of (64)Cu-DOTA-trastuzumab was demonstrated in one patient by autoradiography, immunohistochemistry, and LC-MS/MS.

Conclusions: Cu-DOTA-trastuzumab PET could be a potential noninvasive procedure for serial identification of metastatic brain lesions in patients with HER2-positive breast cancer.

Trial registration: UMIN000004170.

No MeSH data available.


Related in: MedlinePlus